# Use of Rosiglitazone in the Treatment of Endometriosis

> **NCT00115661** · PHASE2 · TERMINATED · sponsor: **Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)** · enrollment: 25 (estimated)

## Conditions studied

- Endometriosis

## Interventions

- **DRUG:** Rosiglitazone

## Key facts

- **NCT ID:** NCT00115661
- **Lead sponsor:** Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-07
- **Primary completion:** 2006-05
- **Final completion:** 2006-05
- **Target enrollment:** 25 (ESTIMATED)
- **Why stopped:** Due to the meta-analysis about CV adverse effects of rosiglitazone.
- **Last updated:** 2012-10-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00115661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00115661, "Use of Rosiglitazone in the Treatment of Endometriosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00115661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*